ArticleFrontiers in neurology
Efficacy, tolerability and barriers to the use of anti-CGRP medications among migraine patients in Egypt: real world experience.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With the introduction of anti-CGRP therapies in Egypt in 2019, there is a growing need to evaluate their real-world use, including effectiveness, tolerability, barriers to access, and treatment adherence among migraine patients. This study aimed to describe the clinical outcomes, tolerability, and barriers to the use of anti-CGRP therapies in an Egyptian cohort. Methods: In this descriptive observational study, migraine patients who were prescribed anti-CGRP therapy were assessed using headache diaries, MIDAS, and HIT-6 at baseline, with follow-up at one and three months after treatment initiation. Patients were also evaluated for background headache and medication overuse headache pre- and post-treatment, the reasons for treatment discontinuation, and relapse rate after drug discontinuation (defined as loss of ≥50% of initial improvement). Results: A total of 80 patients (62 chronic and 18 episodic migraine) received Erenumab, Galcanezumab, or Rimegepant. Overall, 54 patients (68%) showed a favorable ≥50% response, with clinically significant reduction in monthly migraine days, headache severity, duration, HIT-6 and MIDAS scores ( Conclusion: This study provides real-world insights into the use of anti-CGRP therapies among migraine patients in Egypt, demonstrating consistent clinical improvement and good tolerability. It also highlights important challenges related to treatment access and adherence. Findings should be interpreted in the context of observational design of the study, and further controlled studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.